Atlas Trials

Emergent BioSolutions

47 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Emergent BioSolutions

RecordFirmDate
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. (NCT07268612)Emergent BioSolutions2035-11-01
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients (NCT03569553)Emergent BioSolutions2027-05-30
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax (NCT07478471)Emergent BioSolutions2027-05-01
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario (NCT02177721)Emergent BioSolutions2027-01-01
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax (NCT03569514)Emergent BioSolutions2026-11-30
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (NCT05935917)Emergent BioSolutions2023-05-30
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults (NCT05377255)Emergent BioSolutions2022-03-28
Study of SIAN Nasal Spray in Healthy Adults (NCT05194358)Emergent BioSolutions2021-12-21
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults (NCT05142306)Emergent BioSolutions2021-12-07
Universal Influenza A Vaccine in Healthy Adults (NCT05155319)Emergent BioSolutions2021-12-01
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults (NCT04661839)Emergent BioSolutions2020-12-24
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (NCT04067011)Emergent BioSolutions2019-08-12
VELOCITY: An Anthrax Vaccine Clinical Study (NCT03877926)Emergent BioSolutions2019-03-11
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) (NCT03624946)Emergent BioSolutions2018-06-27
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A (NCT03315104)Emergent BioSolutions2017-11-17

Track Emergent BioSolutions automatically

Every clearance here is in the API, with alerts when new ones post.